In the Turku validation cohort, tumors with positive nuclear PHD2 expression had more commonly lower pT‐stage (p < 0.001), lower nuclear grade (p = 0.002), as well as lower rates of microvascular invasion (p < 0.001), histological tumor necrosis (p = 0.001), and sarcomatoid differentiation (p = 0.046). The gene discussed is EGLN1; the disease is neoplasm.